PRNewsWire
02 Jul 2026, 00:11 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Larimar Therapeutics' nomlabofusp study revealed a significant safety signal with anaphylaxis reported in 10 out of 43 patients. — Severe safety issues like anaphylaxis in a high percentage of participants create substantial regulatory hurdles and risk of drug failure.
-0.80Pomerantz LLP is investigating Larimar Therapeutics for potential securities fraud and unlawful business practices. — Class action investigations often lead to costly litigation and create negative sentiment regarding corporate governance.
-0.50Larimar Therapeutics has submitted the first section of its rolling Biologics License Application (BLA) for nomlabofusp. — The submission of a BLA is a positive step toward commercialization, though tempered here by the safety concerns.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is being investigated for securities fraud following severe allergic reactions in clinical trials and significant stock price drops.
The company is the subject of an investigation by Pomerantz Law Firm on behalf of investors.
The company is the subject of an investigation by Pomerantz Law Firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
